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           The  term  "Electrophysiological  remodeling"  defines  the  changes  of  atrial 
electrophysiologic  properties  taking  place  in  atrial  myocites  during  atrial  fibrillation  and/or 
following  periods  of  sustained  atrial  fibrillation  (AF).                     
Early research was prompted by clinical observations: many patients were seen to get through 
increasingly frequent and longer paroxisms of AF to persistent AF, until chronic AF eventually 
ensued,  without  significant  changes  of  underlying  heart  disease.
            Indeed, clinical electrophysiology investigations reported peculiar differences between 
AF patients and patients without atrial arrhythmias. It was felt that the electrophysiologic milieu 
was the cause of AF  1,2,  until  a change of perspective occurred in the early 90's,  thanks to 
experimental  research.                                   
            In his pioneering work, Wijffels kept goats fibrillating by an implanted device, while 
measuring atrial refractoriness and its rate adaptation as spontaneous restoration of sinus rhythm 
occurred. He found that, after several self terminating short bouts of AF, the arrhythmia became 
considerably  longer  until  a  duration  of  days  or  weeks  was  reached.  The  electrophysiologic 
companionship  of  AF  pattern  transformation  consisted  of  significant  shortening  of  atrial 
fibrillation cycle, which was paralleled by shortening of atrial ERP and loss of ERP adaptation to 
heart rate: either flat (no change with shortening cycle length) or inverted (paradoxical shorter 
ERP  at  longer  cycle  length)  ERP  relationships  to  cycle  length  were  observed.  
            This findings had been already observed in AF patients1,2; the novelty was that AF itself 
was the cause of these abnormal  electrophysiologic properties,  which could in turn promote 
further  recurrences  of  AF,  and  arrhythmia  persistence  in  some cases.                     
            By the light of this observations,  AF may be seen as self-maintaining by creating a 
functional electrophysiologic substratum, despite the coexistence of only minor structural heart 
disease or occasional triggers. This principle has been summarised by Maurits Allessie in the 
aphorism  "AF  begets  AF".                                     
            Following this observations, several studies have addressed the issue of the mechanisms 
by  which  atrial  electrophysiologic  remodeling  occurs  in  different  settings:  basic 
electrophysiology,  experimental  electrophysiology,  and  clinical  electrophysiology.  It  is 
nowadays believed that, beyond structural heart disease, changes of the atrial electrophysiologic 
substratum are  responsible  for  AF recurrence  and/or  perpetuation.                         
            The aim of this review will be to assess the extent at which atrial remodeling occurs in 
the  experimental  animal  and  in  humans,  and  its  relevance  to  clinical  practice.
Mechanisms  of  atrial  remodeling                                    
            Reviewing literature, one has to consider carefully the investigational setting of reported 
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studies,  for  significant  differences  exist  in  electrophysiologic  properties  and  vulnerability  to 
atrial arrhythmias among species (small mammals atria hardly fibrillate, dogs and goats only 
under pathologic conditions), so that concepts must lean on solid evidence before moving from 
experimental  to  clinical  electrophysiology,  and  eventually  to  clinical  practice.
            On  the  other  hand,  the  settings  of  experimental  and  basic  electrophysiology  allow 
precisely  controlled  conditions,  and  a  deeper  knowledge  of  the  mechanisms,  up  to  the 
ionic/genomic level.              It is well demonstrated that atrial remodeling is a time-dependent 
process that develops as an adaptive regulation of cardiac myocites to maintain cell homeostasis 
against external stressors 3. The type and extent of remodeling depends on the strength and the 
duration of exposure to the "stressor": adaptive responses may thus occur at the ionic/genomic 
level  (fully  reversible)  at  short  term,  or  at  the  cellular  level  at  mid  (hibernation,  usually 
reversible)  and  long  term  (apoptosis  and  fibrosis,  irreversible).
            The  most  common "stressors"  of  atrial  myocites  are:  tachycardia  (high  rate  of  cell 
depolarisation),  and volume/pressure overload (heart  failure  syndrome).                     
            The adaptive changes at the ionic level are quite different in the tachycardia-dependent 
compared to the heart failure setting, as demonstrated by basic electrophysiology, hence we need 
to  focus  on  different  types  of  "ionic  remodeling".                             
Tachycardia-dependent remodeling: High atrial rate causes calcium overload. Chronic calcium 
overload may cause ultrastructural changes that resemble myocardial ischemia or hibernation, 
and may ultimately lead to irreversible cell damage. To prevent dangerous calcium overload, 
atrial myocites decrease L-type Ca++ current (ICa) at first by a short-term adaptation (functional 
inactivation  by  voltage-  and  [Ca++]  -  dependent  mechanisms),  in  the  long  term  by 
downregulation of ICa4,5,6,7. Decreased ICa shortens action potential duration (refractoriness) 
and  causes  loss  of  action  potential  adaptation  to  heart  rate6,7:  these  are  the  hallmark  of 
tachycardia-dependent  remodeling.                                    
            The  process  leading  to  ICa  downregulation  implies  transcriptional  changes  at  the 
genomic level, but the signal coupling calcium overload to changes in ion channel expression is 
unknown. It also remain to be understood whether calcium overload is the only initiating signal 
in  this  setting.                                   
            The observations by Wijffels et al 8 in the experimental animal are in full agreement with 
this  model  of  atrial  remodeling.  In  patients  with  lone  paroxysmal  AF,  Capucci  et  al  9 
demonstrated a strict correlation of atrial refractoriness to AF cycle, and observed progressive 
shortening of AF cycle during long lasting AF, whereas AF cycle prolonged in self-terminating 
AF episodes. Acute administration of class 1C drugs was able to prolong AF cycle and terminate 
long lasting AF episodes  10.  These data are consistent with basic electrophysiology, and are 
clues that ionic remodeling occurs early during AF, and sets the background for AF recurrence. 
In  the  clinical  scenario,  early  AF recurrence  after  cardioversion  of  chronic  AF is  the  most 
threatened complication. In this setting a typically tachycardia-dependent remodeling occurs: in 
a study of 101 patients 11 we identified loss of atrial refractoriness adaptation to heart rate, short 
atrial refractoriness and AF duration as the only predictors of AF recurrence at logistic analysis.
            In  a  series  of  28  patients,  Manios  et  al  12 similarly  observed  that  failure  of  action 
potential  adaptation  to  heart  rate  was  the  only  prognostic  indicator  for  AF  recurrence. 
Importantly,  they  observed  that  the  electrophysiological  markers  of  tachycardia-dependent 
remodeling  recover  nearly  24  hours  after  AF cardioversion.  This  point  raises  an  important 
question, that is, whether loss of refractoriness adaptation to heart rate is the cause of AF relapse 
(which could explain only AF relapse within 24-48 hours) or simply a "marker" of a pathologic 
atrium, which has already undergone some degree of structural remodeling and thus is prone to 
AF.  Up  to  now,  the  question  is  unresolved.                               
            Owing to this  knowledge,  a considerable  amount of work has been done to test  the 
hypothesis  that  preventing  calcium overload  by   Icablockers   would   prevent   tachycardia-
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dependent remodeling also. Experimental studies found that pre-treatment with verapamil could 
attenuate 13 or prevent 14 rapid pacing-induced shortening of atrial refractoriness at short term (< 
24 hours of rapid pacing), respectively in goats and dogs. Following these observations, Daoud 
15 reported  that  pre-treatment  with  verapamil  reduced  short-duration  (5.6  3.9  minutes)  AF-
induced shortening of atrial refractoriness in humans. In the clinical scenario, Tieleman et al 16 
speculated  that  pre-treatment  with  verapamil  or  diltiazem  was  responsible  for  reduced  AF 
recurrence in the first month after electrical cardioversion, due to attenuated or rapidly reversed 
tachycardia-dependent  remodeling.                                        
            This  hypothesis  fits  poorly  with  the  electrophysiologic  findings  by  Manios12 who 
demonstrated that atrial remodeling recovers spontaneously nearly 24 hours after cardioversion: 
the  role  of  verapamil  is  indeed  unclear.  Clinical  studies  have  failed  to  demonstrated  any 
beneficial effect of verapamil in preventing AF recurrence at long term; indeed, a small effect of 
verapamil pre-treatment could reasonably be expected only in AF of short duration, and does not 
affect the electrophysiologic changes occurring with long-lasting AF 17.                             
            Lee et al17 have performed a very important research in chronically instrumented dogs, 
in which electrophysiologic data were studied at baseline and after creation of a tachycardia-
dependent atrial remodeling, comparing a control group with a verapamil-treated group. Atrial 
refractoriness, dispersion of atrial refractoriness, rate adaptation of atrial refractoriness, atrial 
conduction velocity AF inducibility, and AF duration were evaluated respectively after 1 day, 1 
week, and 6 weeks of rapid atrial pacing. This study demonstrated that verapamil could only 
attenuate  the  refractoriness  shortening  after  1-day  pacing,  but  could  not  prevent  the 
electrophysiologic remodeling at long term (1 and 6 weeks). Furthermore, verapamil did not 
affect atrial inducibility, and increased the duration of induced AF. Consistent with this finding 
is  the  observation  of  increased  fragmented  activity  in  paroxysmal  AF  patients  treated  by 
verapamil, as reported by Kumagay 18, which would favour AF persistence. In his study, Lee 17 
reported a significant depression of atrial conduction velocity after 6 weeks rapid pacing: this 
abnormality had no evidence of recovery during two days of follow-up after pacing had been 
stopped. A similar finding had been previously reported in 2 studies 19,20 of chronic paced dogs, 
and were related to structural abnormalities occurring along time  21. All these data make the 
point that verapamil use is of little value when high atrial rates persist longer than 24 hours, and 
thus  give  an  explanation  to  the  results  observed  in  clinical  practice.
            While demonstrating ICa reduction by downregulation of L-type Ca++ channels, Yue et 
al  6 observed an unchanged inward T-type Ca++ current (ICaT ) even after several weeks of 
rapid atrial pacing, who could thus represent a continuous "spill" of calcium into atrial cells 
undergoing high frequency depolarisations. This prompted Fareh et al 22 to investigate the effect 
of mibefradil, a pure T-type Ca++ blocker, in a chronic rapid-pacing dog model to prevent the 
development of an electrophysiologic substrate for AF. After 1 week of rapid pacing, mibefradil-
treated  dogs  did  not  differ  from  control  dogs  (no  rapid  pacing)  in  any  electrophysiologic 
parameter, except for a slightly increased heterogeneity of atrial refractoriness, whereas placebo-
treated  dogs  had  developed  all  the  characteristic  abnormalities  of  tachycardia-dependent 
remodeling  (easy  AF  inducibility  included).  A  potential  direct  electrophysiologic  effect  of 
mibefradil  was  also excluded in  this  study,  thus  supporting  the  evidence that  prevention  of 
tachycardia-induced remodeling as  the  only  protective  effect  of  mibefradil.  Indeed,  the  AF-
promoting  effects  of  rapid  pacing  were  negatively  correlated  to  mibefradil  plasma 
concentrations,  showing  a  dose-dependent  protection  against  atrial  remodeling.
            In  a  similar  study  on  dogs,  Fareh  et  al  23 also  demonstrated  that  prevention  of 
tachycardia-dependent remodeling is possible with the T-type Ca++ channel blocker mibefradil, 
but  not  with  L-type  Ca++  channel  blockers.                              
            There  is  considerable  evidence  that,  in  tachycardia-dependent  remodeling,  calcium 
overload plays an important role either at short or at long term if high atrial rates persist. In the 
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clinical  setting,  small  benefits  may be observed at  short  term by verapamil,  whereas T-type 
Ca++ channel blockers seem promising to prevent long term remodeling during persistent AF.
            These data support the concept that new therapies should target the development of the 
substrate for AF, as opposed to "traditional" antiarrhythmic therapy which aims to modify the 
product  of  the  arrhythmic  substrate.                                    
Heart failure-dependent remodeling: Heart failure (HF) is the most important clinical syndrome 
associated to AF 24. Heart failure causes important ionic remodeling either at the atrial or at the 
ventricular level by powerful neurohormonal changes. The study of atrial remodeling in HF is 
very difficult  in humans because of the structural  changes caused by underlying myocardial 
pathology, and because of the confounding effect of drugs acting on the neurohormonal milieu 
and  of  antiarrhythmic  agents.  For  this  reason  most  of  available  data  rely  upon  basic  and 
experimental  research,  most  often  on  ventricular  myocites.                          
            Heavy  alterations  in  calcium  handling  are  prominent  in  ventricular  myocites:  the 
sarcoplasmic  carrier  of  Ca++ is  downregulated  in  failing  myocites  25,  leading  to  increased 
cytosolic [Ca++] as a maladaptive attempt to maintain contractility. Sodium-calcium exchanger 
current (NCX) is instead upregulated in HF, acting to compensate the impaired Ca++ removal 
due  to  the  sarcoplasmic  carrier  26,27,28,  to  protect  contractile  function  and  cellular  Ca++ 
homeostasis.  NCX exchanges  one  Ca++ for  three  Na+  ,  thus  carrying  a  net  current  in  the 
direction  of  Na+  transport.  The  net  current  carried  by  NCX  may  cause  delayed 
afterdepolarisation  (DAD)  in  certain  electrophysiologic  situations,  which  proved  to  be 
arrhythmogenic  in  HF  29.                                
            Danshi li et al.  30 created a canine model of rapid ventricular pacing-induced HF, and 
observed for the first time in atrial myocites a decrease in ICa, in Na+ current (Ito), in slow 
rectifying K+ current (Iks), and an increase in NCX. Heart failure decreased both Iks and ICa 
30%,  whereas  atrial  tachycardia  decreases  ICa  70%  without  affecting  Ik  6.  The 
electrophysiologic manifestations were an unchanged action potential duration (APD) at slow 
heart  rates  compared to  control  dogs,  whereas  an increase of  APD at  faster  high rates  was 
observed.
            Thus,  a  peculiar  type  of  remodeling  with  an  attenuated  rate-adaptation  of  atrial 
refractoriness and long APD at high rates is observed in experimental HF. This is quite different 
from atrial tachycardia-dependent remodeling, which shows decreased APD at any cycle length 
and  flat  or  reversed  adaptation  of  refractoriness  to  heart  rate.                        
            The mechanisms of AF onset in the setting of HF must be very different. Structural 
changes (interstitial fibrosis) related to underlying disease cause conduction abnormalities that 
predispose to reentrant arrhythmias, increased NCX may promote DADs by transient inward 
depolarising current, which may be enhanced by high cathecolamine levels and by decreased 
Iks.  It  seems then likely that  AF may be initiated by triggered activity,  in  the HF setting.  
            If a different sort of atrial remodeling occurs in HF, peculiar interventions for targeting 
this  arrhythmogenic  substrate  should  be  sought.                                  
            Danshi Li and co-workers  31 performed an elegant investigation on 15 dogs with HF 
induced by rapid ventricular pacing compared to 10 dogs without HF subjected to rapid atrial 
pacing (RAP), evaluating the effect of dofetilide on vulnerability to AF. It was observed that 
dofetilide, a pure Ikr blocker, was extremely effective in terminating AF and in preventing AF 
reinduction  in  dogs  with  HF-dependent  AF.  On  the  contrary,  dofetilide  was  completely 
ineffective in dogs with atrial tachycardia-dependent AF. The electrophysiologic findings were 
striking: atrial refractoriness was shorter and showed less rate adaptation in RAP vs HF dogs; 
dofetilide increased refractoriness significantly and to a greater extent in HF dogs, whereas it 
had  nonsignificant  effects  in  RAP  dogs.                               
            This finding was related to the increased dependency of atrial refractoriness on Ikr in HF 
dogs,  due  to  downregulation  of  Iks  occurring  in  HF  dogs.                    
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            Significant clinical results were indeed observed by Torp-Pedersen et al 32 investigating 
dofetilide effects in advanced HF patients (class III-IV): a significant proportion of AF patient 
converted  to  sinus  rhythm  by  dofetilide,  and  dofetilide  patients  had  a  significantly  higher 
proportion of sinus rhythm persistence during clinical follow up compared to control patients.
            Nonetheless, AF incidence increases with the severity and the duration of HF despite 
therapeutic  interventions.                          
            Shinigawa  et  al33 studied  the  electrophysiologic  remodeling  occurring  during  atrial 
tachycardia in a canine model when HF was superimposed, and also after reversal of HF was 
allowed  to  take  place.  They  observed  that  the  electrophysiologic  changes  related  to  atrial 
tachycardia were completely attenuated by HF, and that reversal of HF led to normalisation of 
both ventricular and atrial volume and contractility, with recovery of atrial electrophysiologic 
abnormalities. However, extensive interstitial fibrosis had developed compared to a group of 
control  dogs,  and  this  invariably  caused  local  conduction  slowing  and  heterogeneity  of 
conduction  velocity.  This  changes  were  irreversible.                             
            Interestingly, in the same experimental canine model of HF, Danshi Li et al 34 reported 
that angiotensin II causes structural atrial remodeling inducing collagen synthesis by fibroblasts, 
and that enalapril interferes with signal transduction at the cellular level, thereby reducing the 
amount of interstitial fibrosis by 30% compared to control dogs or to hydralazine-treated dogs. 
            These  two  studies  carry  the  important  notion  of  targeting  the  development  of  the 
arrhythmogenic substrate understanding the pathophysiologic mechanisms of the disease or of 
the  clinical  syndrome.                              
            It is interesting to note that, either in atrial tachycardia-dependent or in HF-dependent 
remodeling, both reversible and irreversible changes occur. In either situation, the abnormalities 
due  to  ionic  remodeling  (APD,  refractoriness  and  its  adaptation  to  heart  rate)  appear  to  be 
reversible when the "stressor" is removed, but in the same time structural changes at the cellular 
level  have  occurred,  which  are  irreversible.  This  "structural  remodeling"  adds  slowing  and 
heterogeneity of conduction velocity to the abnormalities of refractoriness in both situations, and 
may  explain  the  reduced  efficacy  of  medical  interventions  in  patients  with  persistent  or 
permanent  AF.                              
            Experimental  research has clearly demonstrated that "electrophysiologically" different 
arrhythmias  share  a  common  electrocardiographic  picture  of  atrial  fibrillation,  and  that  the 
underlying differences  imply peculiar  therapeutic  interventions.                            
            All  these  investigations  have  brought  in  the  clinical  arena  a  new  way  of  thinking 
antiarrhythmic therapy: development of new drugs should be guided by the principle of targeting 
the specific ionic currents depending on the pathophysiologic mechanisms of the arrhythmia, to 
achieve the optimal ratio between efficacy and safety. Also, the concept of preventing structural 
remodeling of atrial myocites should be investigated and promptly brought into clinical practice.
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